Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Silo Pharma ( (SILO) ) is now available.
On July 29, 2025, Silo Pharma, Inc. entered into an asset purchase agreement with Many Ads Inc. to acquire the web-based application software marketed as QwikAgents and the associated domain names qwikagents.com, qwikagents.ai, and qwikagents.co. In exchange for these assets, Silo Pharma issued 2,100,000 shares of its common stock to the seller, reflecting a strategic move to broaden its technology capabilities and digital footprint through an equity-financed acquisition.
The agreement includes customary representations, warranties, and covenants, and Many Ads Inc. agreed to indemnify Silo Pharma against misrepresentations, breaches, third-party intellectual property infringements related to the software, and acts of gross negligence, fraud, or intentional misconduct. This structure is designed to mitigate legal and operational risks associated with integrating the acquired software, thereby offering additional protection for Silo Pharma and its shareholders as the company incorporates QwikAgents into its operations.
More about Silo Pharma
Silo Pharma, Inc. is a publicly traded company that operates in the life sciences and pharmaceutical sector. The company focuses on developing and acquiring innovative technologies and intellectual property, using strategic transactions to expand its portfolio of assets and enhance its position in specialized therapeutic and technology-driven niches.
Average Trading Volume: 956,519
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.87M
For a thorough assessment of SILO stock, go to TipRanks’ Stock Analysis page.